▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #400 by analyst upside · 2026-09-27
CLLS
Cellectis S.A.
Healthcare · Market Cap $148M · P/E 0x
ANALYST PRICE TARGET
+262.2%
implied upside to consensus target
Current Price $1.47
Consensus Target $5.33
Bull Target $10.0
Bear Target $1.3
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
2
Sell
0
52-Week Low $1.25
52-Week High $5.48
YTD Return -69.4%
FUNDAMENTALS
Market Cap $148M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $64M
Profit Margin -102.3%
52-WEEK RANGE
52-Week Low $1.25
52-Week High $5.48
Current Price $1.47
Bear Target $1.3
Bull Target $10.0
● Now $1.47 ● Target $5.33
TRADING DATA
Avg Volume 74K
YTD Return -69.4%
Analyst Count 4
Consensus Buy
Upside to Target +262.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Cellectis S.A. (CLLS) is currently trading at $1.47 with a Wall Street consensus price target of $5.33, implying potential upside of 262.2% over the next 12 months. 4 analysts currently cover CLLS, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $1.3.

CLLS operates in the Healthcare sector with a market capitalisation of $148M. The stock is down 69.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.25 – $5.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

PLX +304.4%
Protalix BioTherapeutics, Inc.
$219M · P/E 11.8x · Buy
XFOR +285.4%
X4 Pharmaceuticals, Inc.
$298M · P/E 2.2x · Buy
CCLD +257.7%
CareCloud, Inc.
$87M · P/E 29.3x · Strong Buy
SABS +253.7%
SAB Biotherapeutics, Inc.
$299M · P/E 13.7x · Buy
SPRO +306.5%
Spero Therapeutics, Inc.
$72M · P/E 8.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CLLS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↓ Downgrade
Overweight → Underweight 2026-09-16 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-09-15 Building track record
Baird - Reiterated
Outperform → Outperform 2026-09-15 Building track record
Citizens ↓ Downgrade
Market Outperform → Market Perform 2026-09-15 Building track record
Barclays ● Initiated
Overweight 2026-05-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-14 Building track record
Clear Street ● Initiated
Buy 2025-12-23 Building track record
Barclays - Reiterated
Overweight → Overweight 2025-10-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
19
out of 100
Coverage depth
12/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →